Tadalafil Tablet, Film Coated
Product Images NDC 68071-5186

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-5186). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5186 6)

Label for Tadalafil 20 mg film-coated tablets, package of 60, by NuCare Pharmaceuticals, Inc. The label includes the NDC 68071-5186-6 and identifies the tablets as almond-shaped, yellow, and debossed with "F J4" on one side. Additional information includes storage instructions and manufacturer details from Ahnmedabad Pharmaceuticals Limited, India.*

FDA Label Image

Figure (Tadalafil Figure1)

Four line graphs depicting the differences in blood pressure measurements between Tadalafil and placebo over time. The graphs show standing systolic and diastolic blood pressure, and supine systolic and diastolic blood pressure, with time in hours on the x-axis and difference in mmHg on the y-axis. Error bars indicate variability in measurements.*

FDA Label Image

Figure (Tadalafil Figure2)

Two line graphs comparing standing and supine systolic blood pressure (BP) changes over 24 hours post-dose. The top graph shows standing systolic BP with two lines for Tadalafil 20 mg & doxazosin 8 mg and placebo & doxazosin 8 mg. The bottom graph shows supine systolic BP changes for the same treatments. Both graphs have time post-dose (hours) on the x-axis and BP change (mmHg) on the y-axis.*

FDA Label Image

Figure (Tadalafil Figure3)

A line graph showing the effect on systolic blood pressure (mmHg) over 12 hours after administration of tadalafil 20 mg or placebo, each combined with 8 mg doxazosin. The graph plots changes in systolic BP against time, comparing morning (08:00) and evening (20:00) dosing schedules for both tadalafil and placebo groups.*

FDA Label Image

Figure (Tadalafil Figure4)

A pharmacokinetic graph showing plasma tadalafil concentration (in micrograms per liter) plotted against time (in hours). The graph compares three dosing regimens: single 20 mg dose, single 5 mg dose, and once-daily 5 mg dose following five consecutive days of administration. Data points include error bars representing variability.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks between tadalafil 5 mg and placebo groups. The x-axis shows treatment duration in weeks; the y-axis shows the change in IPSS Total Score. The tadalafil group shows a greater and sustained decrease compared to placebo, with statistical significance indicated at 12 weeks.*

FDA Label Image

Figure 6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS total score over a 12-week duration for tadalafil 5 mg versus placebo. The x-axis indicates treatment duration in weeks, and the y-axis shows the change in score. The graph demonstrates greater reduction in IPSS score with tadalafil 5 mg compared to placebo, with statistically significant differences marked.*

FDA Label Image

Figure 7 (Tadalafil Figure7)

A line graph depicting the least squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride. The y-axis shows LS mean change, and the x-axis shows weeks of therapy at 0, 4, 12, and 26 weeks. Data points indicate a greater decrease with Tadalafil/Finasteride compared to Placebo/Finasteride at the time points, with statistical significance annotations for differences between groups.*

FDA Label Image

Figure 8 (Tadalafil Figure8)

Line graph showing change from baseline in IPSS total score over 12 weeks of treatment with tadalafil 5 mg versus placebo. The x-axis represents duration of treatment in weeks, and the y-axis indicates the change in symptom score, demonstrating a greater decrease with tadalafil compared to placebo over time.*

FDA Label Image

Chemical Structure (Tadalafil Structure)

Chemical structure of Tadalafil, showing its complex fused ring system including aromatic and heterocyclic components, consistent with the active ingredient Tadalafil in the medication.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.